This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

43/100

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Risk genes beyond APOE

Topic: Brain proteins, microglia and lab models

Plain-language summary

M1 specifically enhanced uptake of Aβ fibrils through reduction of intracellular cAMP levels, without affecting monomeric or oligomeric Aβ internalization. Gpr34 knockdown experiments confirmed GPR34 as the molecular target of M1. An intrahippocampal injection of M1 significantly increased microglial Aβ uptake in vivo, an effect that required functional TREM2 signaling. GPR34 expression was significantly reduced in microglia from AD patients and showed age-dependent decline in both humans and mice. Our findings identify GPR34 as a promising therapeutic target for enhancing microglial Aβ clearance and highlight the potential of GPR34 agonists for AD treatment. The age-dependent decline in GPR34 expression may contribute to reduced Aβ clearance efficiency in aging brains, exacerbating amyloid accumulation. Pharmacological activation of GPR34 represents a novel strategy to counteract impaired Aβ clearance in both aging and AD brains, potentially modifying disease progression through enhancement of microglial phagocytic function.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Etani, H., Takatori, S., Wang, W., Omi, J., Amiya, Y., Akahori, A., et al. (2025). Selective agonism of GPR34 stimulates microglial uptake and clearance of amyloid β fibrils. Alzheimer s Research & Therapy. https://doi.org/10.1186/s13195-025-01891-8

Vancouver

Etani H, Takatori S, Wang W, Omi J, Amiya Y, Akahori A, et al. Selective agonism of GPR34 stimulates microglial uptake and clearance of amyloid β fibrils. Alzheimer s Research & Therapy. 2025. doi:10.1186/s13195-025-01891-8. PMID: 41261421.

BibTeX

@article{etani2025-41261421,
  author  = {Etani, Hayato and Takatori, Sho and Wang, Wenbo and Omi, Jumpei and Amiya, Yusuke and Akahori, Aika and Watanabe, Hirotaka and Sonn, Iki and others},
  title   = {{Selective agonism of GPR34 stimulates microglial uptake and clearance of amyloid β fibrils}},
  journal = {Alzheimer s Research \& Therapy},
  year    = {2025},
  doi     = {10.1186/s13195-025-01891-8},
  pmid    = {41261421},
  url     = {https://doi.org/10.1186/s13195-025-01891-8}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

M1 specifically enhanced uptake of Aβ fibrils through reduction of intracellular cAMP levels, without affecting monomeric or oligomeric Aβ internalization.
Gpr34 knockdown experiments confirmed GPR34 as the molecular target of M1.
An intrahippocampal injection of M1 significantly increased microglial Aβ uptake in vivo, an effect that required functional TREM2 signaling.
GPR34 expression was significantly reduced in microglia from AD patients and showed age-dependent decline in both humans and mice.
Our findings identify GPR34 as a promising therapeutic target for enhancing microglial Aβ clearance and highlight the potential of GPR34 agonists for AD treatment.

Why it matters

This study found that selective agonism of GPR34 with M1 enhanced microglial uptake of Aβ fibrils in vitro and increased microglial Aβ uptake in vivo in a way that required functional TREM2 signaling, while GPR34 expression was reduced in microglia from Alzheimer's patients and declined with age. The authors identify GPR34 as a promising therapeutic target, but this is preclinical work and no treatment has been tested in patients.

New to this subject? Start with our plain-English guide: Genetics →

Study details

Evidence strengthLow

How this study scored 43/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer s Research & Therapy)
Journal's citation record	1 / 4	Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	3 / 7	Cited 15 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	5.0 citations a year over 3 year(s) since 2025
Impact for its field and year	3 / 6	Cited 4.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	2 / 4	Cited 15 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Taisuke Tomita: h-index 65 (OpenAlex, whole career)
Institution's track record	1 / 3	The University of Tokyo: institution h-index 1,463 (OpenAlex)
Multicenter collaboration	2 / 3	OpenAlex lists 7 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41261421)
Free to read	2 / 2	Free to read
Total	43 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.

Related studies in Risk genes beyond APOE from nearby years

Also tagged “tdp-43”

1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →